EP0057 + Olaparib for Small Cell Lung Cancer

"EP0057 has been clinically tested to treat advance directives, ovarian cancer, and primary peritoneal cancer."

"Since 2005, EP0057 has been the focus of numerous clinical trials. The initial trial was sponsored by AstraZeneca and included 98 participants - leading to its Phase 1 drug approval. Currently there are 188 active studies for this medicine occurring in 59 countries across 1468 cities."

"Presently, 188 clinical trials are being conducted in order to research EP0057. Out of those studies, 27 have advanced past the third phase. Despite most of these trials taking place near Houston, Texas, there are 9250 different sites around the world that provide access to this medical treatment."

"Absolutely. Data hosted on clinicaltrials.gov attests to the fact that this medical study is still searching for participants, having been initially posted on May 9th 2016 and recently modified in November 16th 2022. 123 patients from a single trial site are needed to complete the trail."

"This 28-day medical trial will assess the overall response rate of EP0057 plus olaparib in patients with urothelial carcinoma. Secondary objectives include exploring further safety combination effects, determining duration of response and PSA on mCRPC expansion cohort, and noting any adverse event frequency associated with the study regimen."

"Affirmative. Information housed on clinicaltrials.gov reveals that this medical research is presently seeking participants, with the initial post date being May 9th 2016 and latest update occurring November 16th 2022. The team requires 123 subjects from a solitary site to join in the trial."